Tumor cell ligand recognized by autologous NK cell receptor

Tumor cell ligand recognized by autologous NK cell receptor refers to a heterogeneous group of cell surface molecules that mediate the interaction between malignant cells and the host's natural killer (NK) cells. These ligands are broadly categorized into activating ligands, such as MICA, MICB, and ULBPs (which bind the NKG2D receptor), and inhibitory ligands, such as MHC class I molecules and HLA-E (which bind KIRs and NKG2A, respectively) (Shimasaki et al., 2020, Nature Reviews Drug Discovery). In healthy tissues, the balance of these signals prevents autologous cell destruction, but tumor cells often alter ligand expression—upregulating stress-induced activating ligands or downregulating MHC class I—to influence immune detection (Vivier et al., 2011, Science). Therapeutic interventions aim to exploit these interactions through monoclonal antibodies that block inhibitory pathways (e.g., Monalizumab targeting NKG2A) or bispecific killer cell engagers (BiKEs) that bridge NK receptors to tumor-specific ligands (Demaria et al., 2019, Nature). Understanding the landscape of these ligands is crucial for developing personalized immunotherapies and overcoming tumor-mediated immune evasion (Raulet et al., 2013, Annual Review of Immunology).

Other names

NK cell ligandNK cell activating ligandNK cell inhibitory ligandStress-induced ligandNKG2D ligandDNAM-1 ligand

Modulation of NK cell activity through the engagement of activating receptors or the blockade of inhibitory receptor-ligand interactions to promote tumor cell lysis.